Founder of Stromedix, Inc., X4 Pharmaceuticals, Inc. and Padlock Therapeutics, Inc., Michael Gilman presently is Chief Executive Officer & Director at Arrakis Therapeutics, Inc., Scientific Advisor at FutuRx Ltd. and President, Director & Secretary at Padlock Therapeutics, Inc.

He is also on the board of Scholar Rock, Inc., Obsidian Therapeutics, Inc. (former Chief Executive Officer & Director) and Scholar Rock Holding Corp.

He previously occupied the position of Chief Scientific Officer & Executive VP at ARIAD Pharmaceuticals, Inc., Executive Vice President-Research at Biogen, Inc. and Chief Executive Officer at Stromedix, Inc. (a subsidiary of Biogen, Inc.), Senior Vice President-Early-Stage Pipeline at Biogen, Inc. and Chief Executive Officer for Stromedix, Inc. (a subsidiary of Biogen, Inc.) and Director at X4 Pharmaceuticals, Inc.

Michael Gilman received a doctorate from the University of California, Berkeley and an undergraduate degree from Massachusetts Institute of Technology.

- Keine Nachrichten -